MedPath

A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer.

Phase 3
Recruiting
Conditions
Papillary Thyroid Cancer
Interventions
Drug: Preoperative Injection of Carbon Nanoparticles
Drug: Intraoperative Injection of Carbon Nanoparticles
Registration Number
NCT06791005
Lead Sponsor
Second Affiliated Hospital of Xi'an Jiaotong University
Brief Summary

The detection rate of thyroid cancer (PTC) has increased rapidly in recent years. Except undifferentiated cancer, surgery is still one of the most important treatments for all types of thyroid cancer, and there is a consensus to use the lobes of the gland as the minimum extent of resection. In the meantime, a basic consensus has been reached that central zone lymph node (VI) dissection is the minimum extent of lymph node dissection. In clinical practice, neck surgery and lumpectomy are mostly performed. Hypoparathyroidism and recurrent laryngeal nerve injury are the most common complications of radical surgery for thyroid cancer, both in open surgery and the luminal approach. Once these complications occur, they have a serious impact on the quality of life of patients in the postoperative period. A number of contrast agents are now being used to help minimize complications. Carbon nanoparticles are an effective and non-harmful negative developer, and many studies have confirmed that carbon nanoparticles can be used to identify parathyroid glands in thyroid surgery. Intraoperative injection of nanocarbon is effective in increasing the quality of intraoperative parathyroid detection and lymph node clearance and reducing adverse effects, such as postoperative hypokalemia.However, there is no complete clinical guideline for preoperative intraglandular injection of carbon nanoparticles, and there is no standardized dosage for appropriate injection time, injection dose, and injection method. At the same time, there is still the problem of carbon nanoparticle leakage. At our medical center, we have found that preoperative injection of carbon nanoparticles via ultrasound-guided fine needle puncture may yield better results by reducing CNS exudation in the surgical area. In this study, we will collect more than 400 patients who underwent thyroidectomy in 2025 and underwent carbon nanoparticle injections at different time points and analyzed their intraoperative and postoperative conditions as a basis for analyzing the difference in patient benefits between preoperative and intraoperative carbon nanoparticle injections and to provide data to support the clinical use of carbon nanoparticles.

Detailed Description

1. Use of drugs: Carbon nanoparticles, Chongqing Lemay Pharmaceutical Co. Ltd., production license, Food and Drug Administration Production License No. (China) 2007204, Registration No.: State prescription H20041829. The product is a stable suspension of carbon particles with a diameter of 150 nm.2. Preoperative injection method: The preoperative subgroup was injected with carbon nanoparticles 2-6 hours before surgery, with the patient in the position of padded shoulder, and disinfection around the puncture point was prepared prior to the injection of carbon nanoparticles. Under ultrasound guidance, a fine needle was used to puncture the lower 1/3 of the ventral surface, and no blood was detected on aspiration, i.e., 0.1 mL of carbon nanoparticles was injected into each of the 2 sites of each gland, and the total volume of carbon nanoparticles injected was 0.4 mL, and the depth of injection was approximately within the upper third of the gland.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
400
Inclusion Criteria
  • Preoperative pathological assessment indicated the presence of thyroid cancer with a maximum diameter of less than 4 cm.
  • Postoperative pathological evaluation confirmed bilateral thyroid cancer or lateral lymph node metastasis.
  • Vocal cord examination conducted one week prior to surgery revealed no abnormalities.
  • The patient had no history of prior thyroid surgery and required a total thyroidectomy.
  • Blood pressure was stably controlled.
  • The patient regained consciousness and was able to communicate normally.
Exclusion Criteria
  • Prior to enrollment, the patient had received radiotherapy, chemotherapy, or isotope therapy.
  • A documented history of thyroid surgery.
  • Age under 16 years.
  • Known allergies to the medications under investigation or an inability to tolerate surgical intervention.
  • Presence of a retrosternal thyroid tumor.
  • Tumor invasion of the parathyroid glands and/or the recurrent laryngeal nerve during surgical procedures.
  • Postoperative pathology suggestive of medullary carcinoma or undifferentiated carcinoma.
  • Development of a postoperative tracheal fistula.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Preoperative Injection Before Partial Thyroidectomy GroupPreoperative Injection of Carbon NanoparticlesPatients in this group will undergo partial thyroidectomy and preoperative injection of carbon nanoparticles.
Intraoperative Injection During Partial Thyroidectomy GroupIntraoperative Injection of Carbon NanoparticlesPatients in this group will undergo partial thyroidectomy and intraoperative injection of carbon nanoparticles.
Preoperative Injection Before Total Thyroidectomy GroupPreoperative Injection of Carbon NanoparticlesPatients in this group will undergo total thyroidectomy and preoperative injection of carbon nanoparticles.
Intraoperative Injection During Total Thyroidectomy GroupIntraoperative Injection of Carbon NanoparticlesPatients in this group will undergo total thyroidectomy and intraoperative injection of carbon nanoparticles.
Primary Outcome Measures
NameTimeMethod
Gendersup to three years

Data will be summarized in terms of "male" and "female" as units of measurement.

Heightup to three years

The height indicator will summarize the data in "meters".

Weightup to three years

The weight indicator will summarize data in "kilograms".

BMIup to three years

BMI will be summarized in "kg/m\^2".

Tumor Diameter Sizeup to three years

Tumor diameter size will be summarized in "millimeters".

Tumor Locationup to three years

Data will be summarized in terms of "Upper pole of left lobe" , "middle pole of left lobe" , "lower pole of left lobe" , "upper pole of right lobe" , "middle pole of right lobe" , "lower pole of right lobe" , "isthmus" and "multifocal" as units of measurement.

Pathological Resultsup to three years

Data will be summarized in terms of detailed pathological results and "none" .

Preoperative Serum Calciumup to three years

The Calcium indicator will summarize data in "mmol/L".

Preoperative Serum Thyroid Hormoneup to three years

The thyroid hormone indicator will summarize data in "pmol/L".

Preoperative Serum Parathyroid Hormoneup to three years

The parathyroid hormone will summarize data in "pmol/L".

Preoperative serum TSHup to three years

The TSH indicator will summarize data in "mlU/L".

Preoperative Vocal Cord Movement Problems or Laryngoscopy Resultup to three years

Data will be summarized in terms of "normal" , "symptomatic" and "laryngoscopy abnormal" as units of measurement.

Carbon Nanoparticles Injection Siteup to three years

Data will be summarized in terms of "Upper pole of left lobe" , "middle pole of left lobe" , "lower pole of left lobe" , "upper pole of right lobe" , "middle pole of right lobe" , "lower pole of right lobe" , "isthmus" and "multi-site injection" as units of measurement.

Number of Carbon Nanoparticles Injectionsup to three years

Number of Carbon Nanoparticles Injections

Carbon Nanoparticles Injection Doseup to three years

Injection dose will be summarized in "milliliter".

Duration of The Operationup to three years

The duration of the operation will summarize data in "h". The time interval from the induction of anesthesia to the end of surgery was selected as the length of surgery, according to the surgical care records

Thyroid Stainingup to three years

Data will be summarized in terms of "A" ,"B" and "C" as units of measurement. A.The stained thyroid is good in the center and at the margins, with clear staining at the edges; B.The stained thyroid gland has good central staining, and the margins are grossly stained, so that the marginal pattern can be roughly observed; C.The stained thyroid stains well, with poorly stained margins;

Lymph node stainingup to three years

Data will be summarized in terms of "A" ,"B" and "C" as units of measurement. A.The center and margins of the stained lymph nodes are well stained, and the margins are clearly stained; B. The stained lymph nodes have good central staining and grossly stained margins; the marginal pattern can be roughly observed, and the lymph nodes are definite on palpation; C.Good central staining of the stained lymph nodes, unclear staining of the margins, and precise palpation of the lymph nodes.

Parathyroid Glands Stainingup to three years

Data will be summarized in terms of "A" ,"B" and "C" as units of measurement. A.Good central infiltration, uniform and clear staining throughout the gland; B.Central infiltration is good, staining of the entire gland is still uniform, but flaky stained areas are seen, and the gland is exact on palpation; C.Central infiltration is fair, staining of the entire gland is stellate with no obvious shape, and the gland is exact on palpation.

Nanocarbon Leakageup to three years

Data will be summarized in terms of "A" ,"B" and "C" as units of measurement. A.no visible leakage, only slight leakage at the injection site, not affecting the parathyroid glands or the recurrent laryngeal nerve; B.leakage is present and visible to the naked eye, but less than 1/2 of the entire operative field, with staining of the trachea, thyroid peritoneum, and anterior cervical musculature; C.Leakage is present and reaches 1/2 of the entire operative field or Carbon Nanoparticles results in staining of the parathyroid glands or the recurrent laryngeal nerve, affecting identification.

Postoperative Drainageup to three years

The postoperative drainage will summarize data in "milliliter".

Length of Postoperative Hospitalizationup to three years

The length of postoperative hospitalization will summarize data in "days"

Postoperative Serum Parathyroid Hormoneup to three years

The parathyroid hormone will summarize data in "pmol/L".

Numbness of The Hands and Feetup to three years

The numbness of the hands and feet will be summarized with a "yes" or "no" to the data.

Postoperative Laryngeal Recurrent Nerve Irritation and Injuryup to three years

Postoperative laryngeal recurrent nerve irritation and injury will be summarized with a "yes" or "no" to the data.

Postoperative Hematomaup to three years

The postoperative hematoma will be summarized with a "yes" or "no" to the data.

Postoperative Tracheocutaneous Fistulaup to three years

The postoperative tracheocutaneous fistula will be summarized with a "yes" or "no" to the data.

Intraoperative Hemorrhageup to three years

The intraoperative hemorrhage will summarize data in "milliliter".

ageup to three years

Age will be aggregated using "years" as the unit of measurement.

Number of Lymph Node Dissectionup to three years

Record the total number of lymph nodes dissected, the number of lymph nodes dissected in the central region, the number of lymph nodes dissected in the lateral cervical region and the number of metastatic lymph nodes detected.

Duration of Postoperative Painup to three years

The duration of postoperative pain will summarize data in "days".

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

The Second Affiliated Hospital of Xi'an Jiaotong University

🇨🇳

Xi'an, Shaanxi, China

The Second Affiliated Hospital of Xi'an Jiaotong University
🇨🇳Xi'an, Shaanxi, China
Yang Liu, doctor
Contact
0086+029-13384986500
individualliu@163.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.